Lynx1 Capital Management LP 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:07 am Sale | 2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 37,436 2.800% | -84,762 (-69.36%) | Filing |
| 2024-02-14 09:19 am Purchase | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 122,198 9.900% | 51,841 (+73.68%) | Filing |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 70,357 7.600% | 22,550 (+47.17%) | Filing |
| 2022-10-24 4:57 pm Purchase | 2022-10-13 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 47,808 5.100% | 47,808 (New Position) | Filing |